Resources
28 Results (showing 1 - 10)
Results sorted by updated date (oldest first)
Results sorted by updated date (oldest first)
Posted 2/16/2022 (updated 3/26/2024)
In the United States, combined stimulant/opioid overdose mortality has risen dramatically over the last decade. These increases may particularly affect non-Hispanic Black and Hispanic populations. We used death certificate data from the US National Center for Health Statistics (2007–2019) to compare state-level trends in overdose mortality due to opioids in combination with 1) cocaine and 2) methamphetamine and other stimulants (MOS) across racial/ethnic groups (non-Hispanic White, non-Hispanic Black, Hispanic, and non-Hispanic Asian American/Pacific Islander).
Posted 3/21/2022 (updated 3/27/2024)
People who inject drugs (PWID) are likely to experience wounds and infection related to their injection drug use. Common wounds and infections experienced by PWID include blood poisoning (septicemia), infection of the heart lining (endocarditis), tetanus, hepatitis, bruising, collapsed veins, abscesses and blood clots. Preventing and caring for wounds in PWID requires special consideration of the conditions surrounding drug use.
Posted 6/14/2022 (updated 3/27/2024)
Overdose education and naloxone distribution (OEND) to laypersons are key approaches to reduce the incidence of opioid-involved overdoses. While some research has examined attitudes toward OEND, especially among pharmacists and first responders, our understanding of what laypersons believe about overdose and naloxone is surprisingly limited.
Posted 7/12/2022 (updated 3/27/2024)
Syringe services programs (SSP) are harm reduction programs that provide a wide range of services including, but not typically limited to, the provision of new, unused hypodermic needles and syringes and other injection drug use supplies, such as cookers, tourniquets, alcohol wipes, and sharps waste disposal containers, to people who inject drugs. In this summary, readers will find information with respect to SSPs for each state, including citations to applicable statutes and/or regulations, whether the state allows SSPs by statute, whether there are any municipal or county ordinances or regulations in place within the state, program components, miscellaneous provisions, and information on any pending legislation.
Posted 7/25/2022 (updated 3/27/2024)
In 2019, the Addictions, Drug & Alcohol Institute (ADAI) at the University of Washington launched the “Meds First” program to provide onsite, low-barrier access to buprenorphine in partnership with six syringe services programs across WA State. A key component of the Meds First service model was the addition of care navigation to support client engagement and retention in OUD treatment.
Posted 7/25/2022 (updated 3/27/2024)
Drug overdose deaths increased 30% in the United States from 2019 to 2020. Known health disparities exist in overdose mortality rates, particularly among certain racial/ethnic minority populations. Implementation of an evidence-based, culturally responsive, multi-sectoral approach is critical to reducing disparities in overdose rates. This includes addressing structural barriers and enhancing efforts such as linkage to care and harm reduction services.
Posted 8/2/2022 (updated 3/27/2024)
Innovative at their inception three decades ago, drug courts confront a practical and ethical obligation to reimagine some core practices and assumptions. A shifting legal and public health landscape means, for example, increased scrutiny of the courts’ focus on abstinence and mandated treatment, and the use of jail. This publication argues the most effective way for drug courts to evolve is by integrating the practices and principles of harm reduction
Posted 8/23/2022 (updated 3/27/2024)
In this cross-sectional, multistate study of rural communities, 79% of people using drugs reported past-30-day methamphetamine use; nonfatal overdose was greatest in people using both methamphetamine and opioids (22%) vs opioids alone (14%), or methamphetamine alone (6%). People using both substances reported the least access to treatment; only 17% of those using methamphetamine alone had naloxone.
Posted 10/3/2022 (updated 3/27/2024)
Nitazenes are a novel group of powerful illicit synthetic opioids derived from 2-benzylbenzimidazole that have been linked to overdose deaths in several states. Nitazenes were created as a potential pain reliever medication nearly 60 years ago but have never been approved for use in the United States. Laboratory test results indicate that the potency of certain nitazene analogs (e.g., isotonitazene, protonitazene, and etonitazene) greatly exceeds that of fentanyl, whereas the potency of the analog metonitazene is similar to fentanyl.
Posted 4/28/2023 (updated 3/27/2024)
With the proliferation of fentanyl and other adulterants in the national illicit drug supply, people who use drugs (PWUD) are at greater risk of overdose. Among more than 107,000 drug overdose deaths that occurred between July 2021–June 2022, 64% involved synthetic opioids like fentanyl. Lowering the high rates of overdose among PWUD is possible, as evidence-based practices exist to prevent and respond to overdose, including fentanyl test strips and advanced drug checking equipment. To inform health departments’ harm reduction programming, the National Council for Mental Wellbeing – with support from the Centers for Disease Control and Prevention – developed Enhancing Harm Reduction Services in Health Departments: Fentanyl Test Strips and Other Drug Checking Equipment, an educational brief grounded by real-world experience.